The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance

por Toner, A P, McLaughlin, F, Giles, F J, Sullivan, F J, O'Connell, E, Carleton, L A, Breen, L, Dunne, G, Gorman, A M, Lewis, J D, Glynn, S A
Publicado 2013